Clinical Trial Update: Assessing An Oral Janus Kinase Inhibitor, AZD4205 as Monotherapy in Patients Who Have PTCL (JACKPOT8) [Phase 1, Phase 2]

View source ↗

Summary

Results from the Phase 1/2 JACKPOT8 trial of the oral JAK inhibitor AZD4205 as monotherapy in relapsed or refractory peripheral T-cell lymphoma have been posted…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Peripheral T-cell Lymphoma

Drugs mentioned

• AZD4205

Snippet

Sponsor: Dizal Pharmaceuticals | Conditions: Relapsed or Refractory Peripheral T Cell Lymphoma | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2025-04-04